- recruitingPHASE3
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
This study is looking at a new drug, daraxonrasib, for people with pancreatic cancer that has spread. It compares daraxonrasib alone, or with standard chemotherapy (gemcitabine and nab-paclitaxel), against standard chemotherapy by itself. The aim is to see if the new treatments can help people live longer and stop the cancer from growing.
United States · Australia · Austria - recruitingPHASE3
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
This study is testing a new medicine, atebimetinib, alongside standard chemotherapy for pancreatic cancer that has spread. We want to see if this combination works better and is safe for patients who haven't had treatment before.
United States · Australia · Georgia - recruitingPHASE3
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
This study is testing a new drug called zoldonrasib, combined with standard chemotherapy, for people with pancreatic cancer that has spread. It compares this combination to chemotherapy alone, to see if it helps people live longer or stops the cancer from growing for longer. It focuses on a specific type of cancer gene.
United States · United Kingdom - recruitingPHASE2, PHASE3
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
This study is looking into a new treatment called SBP-101 for advanced pancreatic cancer. It combines SBP-101 with standard chemotherapy (nab-paclitaxel and gemcitabine) to see if it helps people live longer and improves their quality of life.
United States · Australia · Austria - active not recruitingPHASE1, PHASE2
A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab
This study is testing new combinations of drugs for advanced stomach and bowel cancers, including anal and pancreatic cancers. We want to see if these treatments are safe and if they help shrink tumors or stop them from growing. It involves several groups, some trying new drug combinations.
Germany